Patents by Inventor Boaz Tirosh
Boaz Tirosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160251410Abstract: Methods of expressing a recombinant polypeptide of interest are provided. Accordingly there is provided a method comprising providing a cell having been contacted with an agent which downregulates an expression of a tuberous sclerosis (TSC) protein or directly inhibits an activity of same; and contacting the cell with a polynucleotide encoding the recombinant polypeptide of interest. Also provided is a method comprising contacting a cell with an agent which downregulates expression of a tuberous sclerosis (TSC) protein or directly inhibits an activity of same; and a polynucleotide encoding the recombinant polypeptide of interest. Also provided are isolated cells, cell cultures and articles of manufacture for recombinant expression of a recombinant polypeptide of interest.Type: ApplicationFiled: September 3, 2014Publication date: September 1, 2016Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.Inventors: Boaz TIROSH, Maya DADIANI
-
Patent number: 8420078Abstract: A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.Type: GrantFiled: February 21, 2006Date of Patent: April 16, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Arthur Machlenkin, Adrian Paz, Boaz Tirosh, Esther Tzehoval
-
Patent number: 7960507Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 27, 2010Date of Patent: June 14, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas, Arthur Machlenkin, Esther Tzehoval
-
Patent number: 7906620Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: GrantFiled: July 28, 2003Date of Patent: March 15, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20100291127Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: July 27, 2010Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: LEA EISENBACH, BOAZ TIROSH, EREZ BAR-HAIM, ADRIAN PAZ, MATITYAHU FRIDKIN, CHERYL FITZER-ATTAS, ARTHUR MACHLENKIN, ESTHER TZEHOVAL
-
Publication number: 20100129410Abstract: A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.Type: ApplicationFiled: February 21, 2006Publication date: May 27, 2010Inventors: Lea Eisenbach, Arthur Machlenkin, Adrian Paz, Boaz Tirosh, Esther Tzehoval
-
Patent number: 7531629Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: March 29, 2006Date of Patent: May 12, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Adrian Paz, Matityahu Fridkin
-
Patent number: 7189414Abstract: The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation, wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and/or the agent which inhibits intestinal drug degradation.Type: GrantFiled: July 31, 2003Date of Patent: March 13, 2007Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Abraham Rubinstein, Michael Friedman, Muhammad Baluom, Boaz Tirosh
-
Publication number: 20060263342Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: ApplicationFiled: July 28, 2003Publication date: November 23, 2006Applicant: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20060194730Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Patent number: 7084249Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 29, 1999Date of Patent: August 1, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20040219216Abstract: The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation,Type: ApplicationFiled: July 31, 2003Publication date: November 4, 2004Inventors: Abraham Rubinstein, Michael Friedman, Muhammad Baluom, Boaz Tirosh
-
Publication number: 20040185107Abstract: The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation,Type: ApplicationFiled: July 31, 2003Publication date: September 23, 2004Inventors: Abraham Rubinstein, Michael Friedman, Muhammad Baluom, Boaz Tirosh
-
Patent number: 6692766Abstract: The present invention relates to a controlled release drug delivery system comprising a drug which is susceptible to enzymatic degradation by enzymes present in the intestinal tract; and a polymeric matrix which undergoes erosion in the gastrointestinal tract comprising a hydrogel-forming polymer selected from the group consisting of (a) polymers which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by intestinal enzymes; and (b) polymers which are not themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inhibiting degradation of said drug by intestinal enzymes; wherein when the matrix comprises a polymer belonging to group (b) the delivery system further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes and when the matrix comprises a polymer belonType: GrantFiled: February 28, 1997Date of Patent: February 17, 2004Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventors: Abraham Rubinstein, Raphael Radai, Michael Friedman, Boaz Tirosh, Muhammad Baluom, Taher Nassar